In contrast, other immunotherapeutic approaches to MM have been very successful, including monoclonal antibodies targeting CD38, signaling lymphocytic activation molecule family member 7 (SLAMF7), antibody–drug conjugate for B-cell maturation antigen (BCMA) and CAR-T [4]. This evidence concerns the gene CD38 and Miyoshi myopathy.